Hypertrophic Cardiomyopathy Program, Division of Cardiology, Toronto General Hospital; Department of Medicine, University of Toronto,Toronto, ON Anthony Ralph-Edwards, MD, FRCSC, Division of ...

Those stages help determine treatment, and they also reflect a patient’s prognosis. Experts say hypertrophic cardiomyopathy ...

A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.

Considering taking supplements to treat hypertrophic cardiomyopathy? Below is a list of common natural remedies used to treat or reduce the symptoms of hypertrophic cardiomyopathy. Follow the ...

If 1 in 500 Americans have hypertrophic cardiomyopathy, why isn’t it more talked about? The HCMA hopes to change that by upending common misconceptions.

With its first AAV gene therapy program, DiNA-001, in development for the treatment of MYBPC3 hypertrophic cardiomyopathy (HCM), the company and its platform is attracting significant partnering ...

Rolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of ...

Hypertrophic cardiomyopathy (HCM ... and the most appropriate investigations for persons suspected of having HCM. Treatment strategies for the disease and its complications are presented briefly.

Hypertrophic cardiomyopathy (HCM ... The primary goals of treatment for HCM are to manage symptoms, halt or slow down the ...